消化器癌細胞におけるJPH203の抗腫瘍効果の差異 by MUTO, Yasuhide & 武藤, 靖英
Different antitumor effects of JPH203 in gastrointestinal cancer cells 
（消化器癌細胞における JPH203 の抗腫瘍効果の差異） 
千葉大学院医学薬学府 
先端医学薬学専攻 
（主任:松原久裕教授） 
武藤 靖英 
 
Abstract 
 
Background/Aim: L-type amino acid transporter 1 (LAT1) is a promising molecular target for 
cancer therapy. The present study aimed to characterize the anti-cancer effects of JPH203, an 
LAT1-selective inhibitor, on gastrointestinal cancer cells. 
Materials and Methods: Three esophageal, two gastric, and two colon cancer cell lines were used. 
Cytotoxic effects of JPH203 were assessed by a WST-8 assay. LAT1 mRNA levels were determined 
by quantitative PCR. The inhibitory property of JPH203 against LAT1 function was examined by a 
transport assay.  
Results: JPH203 treatment significantly reduced the viability of all gastric and colon cancer cells. 
While LAT1 expression levels and inhibitory potencies of JPH203 on LAT1 functions were 
comparable among the cells, all the esophageal cells were resistant to JPH203.  
Conclusion: JPH203 was effective in reducing gastric and colon cancer cells. To clarify its cell 
type-dependent efficacy, identification of the causal factors for JPH203 resistance will be needed. 
 
 
 
 
Introduction 
 
Amino acids serve as essential components of cellular proteins as well as important energy 
sources, and thus they are indispensable for cell proliferation. Among the known amino acid 
transport systems, the system L is responsible for a Na+-independent neutral amino acid uptake 
pathway, including several essential amino acids such as leucine (1-3). The system L consists of 
four members: L-type amino acid transporter 1 (LAT1, SLC7A5), LAT2 (SLC7A8), LAT3 
(SLC43A1), and LAT4 (SLC43A2), with LAT1 and LAT2 requiring heterodimerization with CD98 
to fulfill their transporter functions.  
Experimental and clinical evidence have shown that LAT1 becomes overexpressed during 
the course of development of various solid cancers, including prostate, breast, lung, pancreatic, and 
gastrointestinal cancers (4–7). In these cancers, it has been shown that strong LAT1 immunostaining 
is exclusively observed in cancerous tissues, and LAT1 overexpression thus appears to associate 
with cancer (8). For patients with esophageal cancer, it has been reported that patients with high 
LAT1 expression levels have significantly poorer overall survival and recurrence-free survival rates 
than patients with low expression levels (9). Similar results can be found for patients with 
non-scirrhous gastric cancer, in which high LAT1 expression levels are associated with a lower 
overall survival rate (10). While such an association has yet to be confirmed in colorectal cancer, a 
recent study shows that LAT1 expression levels are higher in cases with a higher degree of invasion 
depth and venous invasion (11). 
Based on its cancer-associated expression profiles together with the fact that LAT1 
provides a supply route for essential amino acids required for cell proliferation, LAT1 has been 
acknowledged as a promising molecular target for cancer therapy. Accordingly, JPH203 (or 
KYT-0353), which is a tyrosine analog, has been developed as a novel anti-cancer agent specifically 
inhibiting LAT1 function (12, 13). It has been presumed that JPH203 shuts down LAT1-mediated 
amino acid uptake in cancer cells, resulting in a nutrient starvation status that will cause retardation 
of cell proliferation and eventually cell death. In accordance with this, anti-cancer effects of JPH203 
have been demonstrated in pre-clinical experiments using several cancer cell types, such as 
cholangiocarcinoma (14), oral cancer (15), osteosarcoma (16), and thymic carcinoma cells (17). 
Furthermore, a first-in-human phase I study examining the effects of JPH203 in 17 patients with 
advanced solid tumors has recently been launched, the ongoing results of which show that JPH203 
is well-tolerated and effective against biliary tract cancer (18). 
 Given the results obtained so far, it can be expected that JPH203 is an emerging anti-cancer 
drug that effectively fights against various solid cancer types. Nevertheless, due to its short history, 
experimental evidence regarding the pharmacological characterization of JPH203 is limited, and 
thus its efficacy profile in several cancer types, including gastrointestinal cancers (esophageal, 
gastric, and colon cancers), remains to be elucidated. 
Therefore, in order to expand our knowledge regarding the pharmacological 
characteristics of JPH203, this study aimed at clarifying its anti-cancer effects on esophageal, 
gastric, and colon cancers using several cell lines that have not been tested so far.
 
Materials and Methods 
 
Cell lines and culture 
 
Human esophageal cancer cell lines (TE5, TE6, and TE14) were kindly provided by Dr. 
Nishihira (Tohoku University, Sendai, Japan). Human gastric adenocarcinoma cell lines (MKN1 
and MKN45) and a human colon adenocarcinoma cell line (Lovo) were obtained from Health 
Science Research Resources Bank (Osaka, Japan), and another human colon adenocarcinoma cell 
line (HT29) was obtained from American Type Culture Collection (Manassas, VA, USA).  
TE cells were cultured in Dulbecco’s Modified Eagle’s medium (DMEM)/Nutrient 
Mixture F-12 Ham (Sigma-Aldrich, St Louis, MO, USA). MKN1 and MKN45 cells were cultured 
in RPMI 1640 Medium (Nacalai Tesque, Kyoto, Japan). Lovo and HT29 cells were cultured in Ham 
F-12 Medium (Sigma-Aldrich) and McCoy’s 5a Medium Modified (Thermo Fisher Scientific, 
Waltham, MA, USA), respectively. All culture media were supplemented with 10% fetal bovine 
serum and penicillin-streptomycin. All cells were cultured in a humidified incubator at 37°C with 
5% CO2. 
 
Cell viability assay 
 
Inhibitory effects of JPH203 on cell proliferation activity were evaluated by a cell viability 
test using the WST-8 kit (Nacalai Tesque) according to the manufacturer’s protocol. Cells were 
seeded in 96-well plates at a density that had been determined by preliminary experiments and were 
cultured for 24 h. The cells were exposed to JPH203 (0.01, 0.1, 1, 3, 10, 30, 50 μM) (MedKoo, 
Morrisville, NC, USA) for 96 h. Following treatment, cell numbers were determined. In different 
experiments, combinatory effects of the following compounds on JPH203 (20 μM) were also 
examined: chloroquine (an autophagy inhibitor, 30 μM) (Wako, Osaka, Japan), SP600125 (a c-Jun 
N-terminal kinase [JNK] inhibitor, 30 μM) (Wako), SL327 (a mitogen-activated protein kinase 
kinase [MEK] inhibitor, 5 μM) (Wako), parthenolide (a nuclear factor-κB [NF-κB] inhibitor, 5 μM) 
(LKT Laboratories, St. Paul, MN), and SB202190 (a p38 inhibitor, 20 μM) (Wako), or AKT 
inhibitor VIII (an Akt inhibitor, 10 μM) (Tokyo Chemical Industry, Tokyo, Japan). Dimethyl 
sulfoxide (DMSO, which is the solvent of the chemicals) was used as a control and set at the final 
concentration of 0.5% throughout the experiments.  
 IC50, which is the concentration at which the cell viability is reduced by half, was 
calculated using GraphPad Prism 7J (GraphPad Software, La Jolla, CA, USA).  
 
TUNEL assay 
 
TE14, MKN1 and Lovo cells were seeded as described above, and were exposed to 30 µM 
JPH203 for 72 h. Apoptosis of treated cells was detected using TUNEL using the in situ Apoptosis 
Detection kit (Takara-bio, Shiga, Japan) according to the manufacturer’s protocol.  
 
Quantitative PCR (qPCR) 
 
LAT1, LAT2, LAT3, and LAT4 mRNA expression levels in gastrointestinal cancer cells 
were quantified by qPCR. Total RNA of gastrointestinal cancer cells was isolated using ISOGEN II 
(Nippon Gene, Tokyo, Japan). First-strand cDNA was synthesized from 1.0 μg of total RNA using 
ReverTra Ace qPCR RT master mix with a gDNA Remover (Toyobo, Osaka, Japan).  
The qPCR analysis was performed using specific primers (Table I) and Thunderbird 
SYBR qPCR Mix (Toyobo). The relative expression levels were determined using the ΔΔCt-method 
with β-actin mRNA level as a normalization control. 
 
Leucine transport assays 
 
LAT1 function, along with the inhibitory effect of JPH203, in gastrointestinal cancer cells 
was examined by transport assays using L-leucine (leucine), which is a prototypical LAT1 substrate. 
Two days after gastrointestinal cancer cells had been seeded in a 24-well plate (104 cells/well), the 
transport assay was performed. The cell culture medium was replaced with Hanks’ solution and 
pre-incubated for 5 min. The solution was then replaced with fresh Hanks’ solution with leucine 
(containing [14C]leucine at 0.1 mCi/ml) (PerkinElmer, Boston, MA) at the final concentration of 1.0 
μM, and the cells were incubated for one min at 37ºC. In the inhibition assays, JPH203 (10 μM) or 
excess amount of non-radiolabeled leucine (500 μM) were also added to the substrate solution. 
After washing three times with cold Hanks solution, the cells were solubilized with 0.1N NaOH and 
their radioactivity was determined using a β-scintillation counter (2810TR, Perkin Elmer). Uptake 
activity was normalized for protein content, which was determined by a Pierce BCA protein assay 
kit (Thermo Fisher Scientific). Finally, the background activity (which was obtained in the presence 
of excess cold leucine [500 μM]) was subtracted from each uptake activity.
 
Results 
 
Growth inhibition profile of human gastrointestinal cancer cells treated with JPH203 
 
To examine the effects of JPH203 on esophagus (TE5, TE6 and TE14), gastric (MKN1 
and MKN45), and colon (Lovo and HT29) cancer cell proliferation, the cells were treated with 
JPH203 at various concentrations for 96 h and then WST-8 assays were performed. As shown in 
Figure 1, the growth rates of MKN1, MKN45, Lovo, and HT29 cells were significantly reduced 
upon JPH203 treatment: For example, at 50 μM of JPH203, the growth rates of the cancer cells 
were 45.0 ± 3.9%, 17.8 ± 3.5%, 5.0 ± 0.7%, and 33.0 ± 3.7% of the growth rate of control cells, 
respectively. Therefore, the results clearly show that JPH203 exerts inhibitory effects on the growth 
of gastric and colon cancers. 
In contrast, all TE cells were highly resistant to the treatment (64.6 ± 10.4%, 76.0 ± 10.2%, 
80.4 ± 7.6%, respectively) even at 50 μM.  
The IC50 values of JPH203 in gastrointestinal cells are summarized in Table II. 
 
Induction of apoptosis by JPH203 in gastrointestinal cancer cells 
 
In order to determine whether the inhibition of cell proliferation by JPH203 resulted from 
its static effects or induction of cell death, TUNEL assays were performed (Figure. 2). Increased 
staining in MKN1 and Lovo cells, indicates that apoptosis is involved in JPH203-mediated cell 
death. As expected, TE14 cells, which were resistant to JPH203, did not show any sign of apoptosis. 
 
Expression profile of LATs in gastrointestinal cancer cells 
 
To compare the mRNA expression levels of LAT1, LAT2, LAT3, and LAT4 in gastrointestinal 
cancer cells, qPCR was performed (Figure 3). LAT1 mRNA expression was clearly observed in all 
the cells examined. LAT2 and LAT3 mRNA expression and, to a lesser extent, LAT4 mRNA 
expression were observed in some cells, but their levels were substantially lower than those of 
LAT1. Of note, the mRNA expression levels of these LAT members were not apparently related to 
the JPH203 sensitivity profile of the cells. 
 
Leucin uptake activities and their Inhibition by JPH203 in gastrointestinal cancer cells 
 
Leucine uptake activities in the presence of Na+ were examined to characterize LAT1 
functional levels as well as the inhibitory effect of JPH203 on LAT1 function in gastrointestinal 
cancer cells. As shown in Figure 4A, leucine uptake activity was clearly detected in all cancer cells 
regardless of their JPH203 sensitivity profiles. Furthermore, these activities were considerably 
suppressed in the presence of JPH203 to comparable degrees, and these suppressed fractions 
accounted for 70-90% of total uptake in each cell type (Figure 4B).  
Thus, our results suggest that while LAT1 is responsible for most of the leucine uptake 
activity, no striking differences in its functional levels as well as its sensitivity profile against 
JPH203 were observed among esophageal, gastric and colon cancer cells. 
 
Exploration of a JPH203 resistance factor in esophageal cancer cells 
 
In order to obtain insights into a causal factor for the resistance of TE5, TE6 and TE14 
cells in JPH203, exploratory experiments were performed. First, considering that autophagy activity 
may counteract amino acid deficiency, chloroquine (an autophagy inhibitor) was added in 
combination with JPH203. However, it did not ameliorate JPH203 resistance (data not shown).  
Next, effects of inhibitors for cell survival signaling pathways (JNK, MEK, NF-κB, p38, 
and AKT) on cell proliferation were examined in the presence or absence of JPH203. Unfortunately, 
however, the inhibitors did not show any synergistic effects with JPH203 (data not shown).
 
Discussion 
 
The efficacy of JPH203 has not been examined in any cell lines used here (except for 
HT29 cells), and is shown for the first time that JPH203 efficiently inhibits growth rate of gastric 
cancer cells. Also, clear susceptibility of Lovo cells to the agent is consistent with the results of a 
previous study using HT29 cells (12). Therefore, these findings indicate the promising possibility 
that JPH203 is effective against gastric and colon cancers, which will not only encourage further 
JPH203 development studies but also contribute to the establishment of LAT1 inhibition as an 
emerging, as well as promising, concept of anti-cancer treatment. 
Aside from these exciting views, a lack of (or very weak) anti-cancer effects of JPH203 on 
all the esophageal cancer cells examined was found. This might result from either their nature of 
esophageal origin or their own intrinsic properties. While it is currently unknown which is true, this 
finding may provide an important insight into future JPH203 development studies. That is, it is 
possible that JPH203 shows a patient- or tissue-dependent activity. Since therapeutic effects of 
anti-cancer drugs generally vary among patients or tissues, it is not so surprising if this is the case 
for JPH203. Rather, the critical point is to identify how JPH203 efficacy differs and what can 
determine it. 
 Most of the studies on JPH203 have focused on its efficacy (12-17), and the causal factor 
for the development of resistance of certain cancer cells has thus not been identified. Nevertheless, 
based on the mode-of-action of JPH203, it seems reasonable to hypothesize that loss of LAT1 in TE 
cells or aberrant LAT1 sensitivity to JPH203 might play a role in the acquired resistance in 
esophageal cancer cells. However, the fact that LAT1 expression levels are comparable among the 
cell lines tested and the fact that JPH203 reduced leucine uptake activity (namely LAT1 function) to 
similar levels in all cells do not support the LAT1-related hypotheses. Therefore, JPH203 resistance 
of TE cells is unlikely to be explained by LAT1 functionality. Importantly, this point leads to the 
possibility that while LAT1 detection in cancer tissues warrants JPH203-based therapy, it does not 
always ensure its efficacy; that is, significant individual differences in the therapeutic effects in 
LAT1-positive patients can be expected. 
On the other hand, our results also indicate that there should be another factor (or other 
factors) causing JPH203 resistance. In an attempt to identify the factor(s), the following two 
possibilities were examined: 1) counterbalancing leucine deficiency with compensatory activation 
of its supply pathways and 2) enhancing cell survival systems that fight against amino acid 
starvation-induced cell death. 
 As for the first possibility, the involvement of amino acid transporters other than LAT1 in 
compensatory supply of essential amino acids is unlikely. This is because, although such transporter 
activity can be detected (i.e., JPH203-resistant uptake fractions), their overall contribution to 
leucine uptake is low and they are not significantly different among the cells. Consistently, LAT2-4 
mRNA expression, if any, is low, and there is no remarkable difference between their expression 
levels in TE cells and other cells. Additionally, the possibility of intracellular leucine pool 
manipulation through autophagy, which is a well-known process by which cells can obtain amino 
acids in a starved condition was examined (19, 20). Unfortunately, however, the results cannot 
explain the JPH203 resistance profile. 
Given that compensatory leucine supply is unlikely to occur following JPH203 treatment, 
the second possibility was tested. However, blockade of NF-κB, Akt, MAPK, p38, JNK signals did 
not augment JPH203 efficacy, suggesting that these survival signaling pathways are not involved in 
the JPH203 resistance of TE cells. 
 Taken together, the mechanisms underlying JPH203 resistance in TE cells are currently 
unknown. Our results indicate that JPH203 resistance can be acquired not always by lack of LAT1 
but also by other unidentified factors. Identification of such resistance factors will be essential for 
facilitating precision medicine in JPH203 treatment. Furthermore, identification of the resistance 
factors will pave the way for the development of an approach to overcome resistance, which will 
dramatically improve the efficacy of JPH203-based therapy.  
Considering their clinical importance, we should keep striving to identify JPH203 
resistance factor(s) in the future. For example, comparison of trans-omics profiling between 
JPH203-sensitive and -insensitive cells may provide some clues on new molecules and intracellular 
pathways involved in the resistance to JPH203. Moreover, the possibility that JPH203 has an 
additional pharmacological target other than LAT1 should be borne in mind. If intracellular JPH203 
plays a certain role in its anti-cancer activity, it is worthwhile to consider the potential involvement 
of intracellular JPH203 metabolism and excretion. 
To summarize, our results clearly show that JPH203 effectively inhibits growth of gastric 
and colon cancer cells, paving the way for further development of JPH203. Our results also suggest 
that LAT1 is not an exclusive factor predicting JPH203 efficacy. The primary factors causing 
JPH203 resistance remain elusive. However, since biomarkers for efficacy prediction will play an 
important role in JPH203-based cancer treatments, efforts for their identification should be made in 
the future.
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Tables 
 
Table I. Primers 
mRNA  Primer (5’ > 3’) 
LAT1 forward TGTACGTGCTGACCAACCTG 
 reverse ATGACGCCCAGGTGATAGTTC 
LAT2 forward CACGGTTGCTGGACAGATAG 
 reverse GGGAACAGCAGGTTGATCTT 
LAT3 forward ATGGACTGGCGGATCAAGG 
 reverse TCTTGCAGTAGCGTGGTCTGATG 
LAT4 forward GGTGGACAAGTTTCTGCTGAGTG 
 reverse CAGCTGTATGAGGATGCGGTGTA 
β-actin forward CCAACCGCGAGAAGATGA 
 reverse CCAGAGGCGTACAGGGATAG 
 
 Table II. IC50 values 
 Cell line TE5 TE6 TE14 MKN1 MKN45 Lovo HT29 
IC50
a (μM) - - - 41.7 ± 2.3 4.6 ± 1.0 2.3 ± 0.3 30.0 ± 6.4 
a hyphens indicate that the value cannot be calculated. 
 
Figure legends 
  
Figure 1. Effects of JPH203 on the viability of gastrointestinal cancer cells.  
 
Esophagus (TE5, TE6 and TE14), gastric (MKN1 and MKN45), and colon (Lovo and HT29) cancer 
cells were treated with JPH203 at various concentrations for 96 h, and their viabilities were 
analyzed using the WST-8 assay. The viability at each concentration (%) was calculated with 
respect to the control value (100%), which was obtained from cells treated with DMSO (0.5%). 
Data are expressed as means with S.D. Using these results, the IC50 value for each cell type was 
calculated (Table II). The experiments were repeated three to five times, in triplicate. 
 
Figure 2. Detection of JPH203-induced apoptosis in gastrointestinal cancer cells. 
 
Fragmented DNA associated with JPH203-induced apoptosis was detected by TUNEL staining. 
JPH203-sensitve (MKN1 and Lovo) and -resistant (TE14) cells were incubated with JPH203 (30 
μM) for 72 h. The cells with dark staining of nuclei (arrows) were designated as apoptotic cells. The 
experiments were repeated three times, and representative results are shown. 
 
Figure 3. Quantification of mRNA expression levels of LAT family members in 
gastrointestinal cancer cells.  
 
qPCR was performed to determine LAT1, LAT2, LAT3, and LAT4 mRNA expression levels in each 
cell type. Experiments were performed at least three times, in duplicate. The expression levels were 
normalized to those of β-actin, and data are expressed as means with S.D. 
 
Figure 4. Determination of leucine uptake activities and their sensitivities against JPH203 in 
gastrointestinal cancer cells. 
 
Leucine uptake activities in gastrointestinal cancer cells were determined by transport assays using 
[14C]leucine (1 μM) in the presence (+) or absence (-) of JPH203 (10 μM). The transport assays 
were conducted in the presence of Na+. The gray bars indicate LAT1-independent leucine uptake 
activities. A and B show the absolute uptake activity and relative uptake activity, respectively. In B, 
the values in the absence of JPH203 were set at 100%. Determinations were performed three to five 
times, in duplicate. Each value represents the mean with S.D. 
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